Saturday 17 October 2026 Export ARGX’s income statement to Excel — free account

argenex SE

argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024. In the quarter to June 2026, revenue grew 59.5%, EPS grew 88.6% and free cash flow grew 537.5%, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.

819.14 27.13 −3.21%

Follow ARGX

Alert me

Market cap: $53.2B
P/E: 29.6×
Fwd P/E: 32.4×
Dividend yield: —
F-score: 5/9
Altman Z: 24.36
Beneish M: −1.51
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

argenex SE (ARGX) P/E ratio

Alert me on P/E ratio

As of 16 October 2026, argenex SE (ARGX) trades at a P/E ratio of 29.6×. Over the past ten years it has ranged from 0.0× (December 2024) to 48.8× (February 2025); the current reading is higher than 82% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ARGX/pe-ratio" width="100%" height="360" style="border:0" loading="lazy" title="argenex SE P/E ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ARGX/metrics/pe-ratio">argenex SE (ARGX) P/E ratio — stockrow.com</a></p>

Period	P/E ratio	Change
FY2025	40.0×	(10.57%)
FY2024	44.7×	—
FY2023	0.0×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2019	0.0×	—
FY2018	0.0×	—
FY2017	0.0×	—
FY2016	0.0×	—

Period	P/E ratio	Change
Jun 2026	33.5×	10.73%
Mar 2026	30.2×	(24.38%)
Dec 2025	40.0×	36.56%
Sep 2025	29.3×	12.09%
24 more quarters	Free account

Against its own ten years

Low 0.0× High 48.8×

Ten-year median 0.0×

Current reading's percentile 82

Company	P/E ratio
ROIV Roivant Sciences Ltd. compare	n/m
MRNA Moderna, Inc. compare	n/m
RVMD Revolution Medicines, Inc. compare	n/m
INCY Incyte Corporation compare	13.9×
REGN Regeneron Pharmaceuticals, Inc. compare	18.9×
ARGX argenex SE	29.6×
ALNY Alnylam Pharmaceuticals, Inc. compare	39.5×
RPRX Royalty Pharma PLC compare	42.3×
ONC BeOne Medicines Ltd. - Sponsored ADR compare	62.6×
Biotechnology industry median	8.5×
Healthcare sector median	23.0×
Market median	18.1×

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

argenex SE (ARGX) P/E ratio

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on ARGX

P/E ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/E ratio against peers

What P/E ratio is

More on ARGX

Stockrow Weekly